Is this your firm? Get featured or correct your listing →
Recent changes
- Jun 18, 2026Jun 18, 2026New fund: NeoGenesis Capital Fund I SEC EDGAR Form D
Funds
1| Fund | Vintage | Size | Strategy | Source |
|---|---|---|---|---|
| NeoGenesis Capital Fund I | 2026 | — | Flagship | As of Jul 1, 2026SEC EDGAR Form D |
Latest Pulse
- Oct 17, 2026NeoGenesis Capital Launches To Back Colossal BiosciencesXPRIZE founder Peter Diamandis and biologist Yianni Psaltis closed the first fund of NeoGenesis Capital, a venture firm built to back Colossal Biosciences and startups spun from its programmable-biology platform.→
- Oct 14, 2026Colossal's New AI Platform Maps A Path Back To The DodoColossal Biosciences unveiled GenoMorph, an AI platform combining genomics and developmental biology that has already flagged about 2,300 candidate gene edits for reviving the dodo's skull shape.→
- Aug 20, 2026Colossal Spinout Astromech Hits $3.8B on Biology AIAstromech, a Colossal Biosciences spinout co-founded by Ben Lamm and George Church, raised $20M at a $3.8B valuation to build AI models that predict evolutionary biological change.→
Sources & methodologyshow
Where these figures come from
- SEC EDGAR Form Dprimary source1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.